| Name | Title | Contact Details |
|---|
PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market.
Paragon 28 was established for unmet needs of the foot and ankle community. Dedicated to creating solutions to improve the treatment of foot and ankle conditions.
Althera Pharmaceuticals, a company focused on heart health, announces FDA approval of Roszet (rosuvastatin and ezetimibe) tablets. Founded in 2010, Althera develops innovative patient focused medicines to improve cardiovascular health.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Novacea, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.